Table 1.
Plasmids used in this study
| Plasmid name | Vector | Insert(s) | Reference |
|---|---|---|---|
| pACT2 | pACT2 | None | Clontech |
| pACT2-HIF1α | pACT2 | Human full-length HIF1α | This study |
| pACT2-HIF1αPPAG | pACT2 | Human full-length HIF1α P402A/P564G | This study |
| pACT2-DGKι1-1065 | pACT2 | Human full-length DGKι | This study |
| pACT2-DGKι1-878 | pACT2 | Human DGKι aa 1–878 | This study |
| pACT2-DGKι1-667 | pACT2 | Human DGKι aa 1–667 | This study |
| pACT2-DGKι879-1065 | pACT2 | Human DGKι aa 879–1065 | This study |
| pACT2-DGKι668-1065 | pACT2 | Human DGKι aa 668–1065 | This study |
| pACT2-DGKι1-1065PPAA | pACT2 | Human full-length DGKι P147A/P903A | This study |
| pACT2-DGKι879-1065PA | pACT2 | Human DGKι aa 879–1065 P147A/P903A | This study |
| pBridge-pVHL/empty | pBridge | Human pVHL aa 54–213 (MCS 1) | This study |
| pBridge-pVHL/PHD1 | pBridge | Human pVHL aa 54–213 (MCS 1) | This study |
| Human full-length PHD1 (MCS 2) | |||
| pBridge-pVHL/PHD2 | pBridge | Human pVHL aa 54–213 (MCS 1) | This study |
| Human PHD2Δ76–177 (MCS 2) | |||
| pBridge-pVHL/PHD3 | pBridge | Human pVHL aa 54–213 (MCS 1) | This study |
| Human full-length PHD3 (MCS 2) | |||
| pBridge-empty/PHD1 | pBridge | None (MCS 1) | This study |
| Human full-length PHD1 (MCS 2) | |||
| pBridge-empty/PHD2 | pBridge | None (MCS 1) | This study |
| Human PHD2Δ76–177 (MCS 2) | |||
| pBridge-empty/PHD3 | pBridge | None (MCS 1) | This study |
| Human full-length PHD3 (MCS 2) | |||
| pCMV2B-pVHL19 | pCMV2B | Human pVHL aa 54–213 | This study |
| pCMV2B-pVHL30 | pCMV2B | Human pVHL aa 1–213 | This study |
| pcDNA-HA-DGKι | pCMV-HA | Human full length DGKι | Ref. 20 |
MCS, multiple cloning site; pVHL, von Hippel-Lindau protein; PHD, prolyl hydroxylase; DGK, diacylglycerol kinase.